Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 2/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | OTC | P00480 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Name SCHEMBL14751988 | 1.00 | NOS1 (0.41) | NOS1DPP7NOS3NOS2ALDH1A1 | |
| L-Name SCHEMBL18812631 | 0.99 | NOS1 (0.40) | NOS1DPP7NOS3NOS2ALDH1A1 | |
| L-Name SCHEMBL25310005 | 0.99 | NOS1 (0.40) | NOS1DPP7NOS3NOS2ALDH1A1 | |
| SCHEMBL836044 | 0.92 | ALDH1A1 (0.34) | NOS1ALDH1A1 | |
| SCHEMBL12556180 | 0.87 | MEN1 (0.39) | NOS1DPP7NOS3NOS2DPP8 | |
| Nitroarginine SCHEMBL28365071 | 0.84 | NOS1 (0.48) | NOS1NOS3NOS2OTC | |
| SCHEMBL5983469 | 0.84 | NOS1 (0.46) | NOS1DPP7NOS3NOS2OTC | |
| Nitroarginine SCHEMBL345312 | 0.84 | NOS1 (0.48) | NOS1NOS3NOS2OTC | |
| Nitroarginine SCHEMBL881062 | 0.84 | NOS1 (0.48) | NOS1NOS3NOS2OTC | |
| SCHEMBL607060 | 0.84 | NOS1 (0.46) | NOS1DPP7NOS3NOS2OTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1099 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102400-A1 | PHARMACEUTICAL COMPOSITION FOR DISRUPTING TUMOR BLOOD VESSELS | SAMSUNG MEDICAL FOUND (KR) | 2026-04-16 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| US-20250367371-A1 | HYBRID BIOELECTRONIC/ENGINEERED CELL IMPLANTABLE SYSTEM FOR THERAPEUTIC AGENTS DELIVERY AND APPLICATIONS THEREOF | UNIV NORTHWESTERN (US) | 2025-12-04 | — | — | US | claimed |
| US-20250276085-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-09-04 | — | — | US | claimed |
| EP-4591865-A1 | PHARMACEUTICAL COMPOSITION FOR DISRUPTING TUMOR BLOOD VESSELS | Samsung Medical Foundation (KR) | 2025-07-30 | — | — | EP | claimed |
| WO-2025122600-A1 | COMPOSITIONS AND METHODS FOR TREATING ABERRANT NITROSYLATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | claimed |
| CN-120091822-A | Pharmaceutical composition for tumor vascular blockage | 三星医疗财团 | 2025-06-03 | — | — | CN | claimed |
| CN-119969334-A | Method for constructing heart failure and pulmonary artery high pressure animal model | 中国医学科学院基础医学研究所 | 2025-05-13 | — | — | CN | claimed |
| WO-2025091023-A1 | ENGINEERED CELL TRANSFECTED BY ALL-IN-ONE VECTOR FOR THERAPEUTIC AGENTS PRODUCTION AND DELIVERY AND APPLICATIONS THEREOF | NORTHWESTERN UNIVERSITY (US) | 2025-05-01 | — | — | WO | claimed |
| WO-2022153308-A1 | TOPICAL COMPOSITION | RICH PSC LTD. (IL) | 2022-07-21 | — | — | WO | claimed |
| EP-3967303-A1 | INOS-INHIBITORY COMPOSITIONS AND THEIR USE AS BREAST CANCER THERAPEUTICS | The Methodist Hospital (US) | 2022-03-16 | — | — | EP | claimed |
| EP-3154585-B1 | USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY | GREEN KATHY A (US) | 2022-02-23 | — | — | EP | claimed |
| WO-2022035049-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | 동국대학교 산학협력단 | 2022-02-17 | — | — | WO | claimed |
| US-20220040298-A1 | USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY | DARTMOUTH COLLEGE (US) | 2022-02-10 | — | — | US | claimed |
| EP-2256498-B1 | Methods of diagnosing or treating irritable bowel syndrome and other disorders | CEDARS SINAI MEDICAL CENTER (US) | 2015-04-08 | — | — | EP | claimed |
| CN-101594885-A | Rifaximin anti-rectal dysfunction preparation | SALIX PHARMACEUTICALS INC (US) | 2009-12-02 | — | — | CN | claimed |
| EP-1920776-A1 | Prevention of damage in hippocampus of fetus/newborn infant due to maternal gestational hypertension | Kindway International Ltd. (CN) | 2008-05-14 | — | — | EP | claimed |
| US-20080038288-A1 | Prevention of damage in hippocampus of fetus/newborn infant due to maternal gestational hypertension | KINDWAY INTERNATIONA LIMITED (HK) | 2008-02-14 | — | — | US | claimed |
| WO-2002080893-A1 | TREATMENT OF LOW BACK PAIN AND WHIPLASH ASSOCIATED DISORDER | A+ SCIENCE INVEST AB (SE) | 2002-10-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102400-A1 | PHARMACEUTICAL COMPOSITION FOR DISRUPTING TUMOR BLOOD VESSELS | RNMT, PNP, NOS1 | NOS1 3/4885DPP7 2682/4885NOS3 4/4885 |
| US-20250276085-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | STING1, CGAS, GMPS | NOS1 4/4885DPP7 1058/4885NOS3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.